EPIDEMIOLOGY OF HEPATITIS-C VIRUS - A STUDY OF MALE BLOOD-DONORS IN SAUDI-ARABIA

被引:41
作者
ABDELAAL, M
ROWBOTTOM, D
ZAWAWI, T
SCOTT, T
GILPIN, C
机构
[1] King Khalid National Guard Hospital, Jeddah, 21423
关键词
D O I
10.1046/j.1537-2995.1994.34294143941.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Few epidemiologic reports on the prevalence of hepatitis C in Saudi blood donors have been published. Study Design and Methods: Men (of several nationalities) donating blood at the King Khalid National Guard Hospital (Jeddah,Saudi Arabia) were randomly selected (n = 744) for this study examining the prevalence of hepatitis C virus (HCV) In the local donor population, the relationship of antibody to HCV (anti-HCV) to the Surrogate markers alanine aminotransferase (ALT) and antibody to hepatitis B core antigen (anti-HBc), and the effect of the use of these markers on the discard rate. Results: The prevalence of anti-HCV in the group examined was 3.2 percent (24/744), with a significantly high prevalence of 24.5 percent (12/49) in donors who were Egyptian (p<0.0001). Exclusion of this group would lower the prevalence to 1.7 percent (12/695). Anti-HCV prevalence peaked in the group aged 30 to 39, and a significant relationship was: found between anti-HCV and ALT level >65 U/L(p<0.0001). There was no significant relationship between anti-HCV and anti-HBc (p = 0.66). The prevalence of anti-HCV in the Saudis studied was 1.7 percent (9/528). The prevalence bf anti-HCV in non-Bedouin Saudis was significantly greater than that in Bedouin Saudis (7/165 [4.2%] vs. 2/363 [0.5%]; p<0.01). The prevalence of anti-H Be was found to be 28.7 percent (214/744). The use of elevated ALT (>90 U/L) and anti-HBc as surrogate markers would increase the current discard rate (8.3%) by 8.8 and 23.8 percent, respectively. Conclusion: These findings demonstrate the practical difficulties of using anti-HBc as a surrogate marker for hepatitis C in areas endemic for hepatitis B virus.
引用
收藏
页码:135 / 137
页数:3
相关论文
共 13 条
[1]  
ALBANO A, 1992, EUR J EPIDEMIOL, V8, P309
[2]   HEPATITIS B-INFECTION IN SAUDI-ARABIA [J].
ALFALEH, FZ .
ANNALS OF SAUDI MEDICINE, 1988, 8 (06) :474-480
[3]  
ALNASSER MN, 1992, ANN TROP PAEDIATR, V12, P211
[4]   DETECTION OF ANTIBODY TO HEPATITIS-C VIRUS IN PROSPECTIVELY FOLLOWED TRANSFUSION RECIPIENTS WITH ACUTE AND CHRONIC NON-A-HEPATITIS, NON-B-HEPATITIS [J].
ALTER, HJ ;
PURCELL, RH ;
SHIH, JW ;
MELPOLDER, JC ;
HOUGHTON, M ;
CHOO, QL ;
KUO, G .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1494-1500
[5]   ANTI-HEPATITIS-C VIRUS IN BLOOD-DONORS WITH RAISED ALT LEVELS [J].
BELLOBUONO, A ;
MOZZI, F ;
ZANUSO, F ;
ALMINI, D ;
ZANELLA, A .
TRANSFUSION, 1990, 30 (04) :382-382
[6]   HEPATITIS-C VIRUS - THE MAJOR CAUSATIVE AGENT OF VIRAL NON-A, NON-B HEPATITIS [J].
CHOO, QL ;
WEINER, AJ ;
OVERBY, LR ;
KUO, G ;
HOUGHTON, M ;
BRADLEY, DW .
BRITISH MEDICAL BULLETIN, 1990, 46 (02) :423-441
[7]   LOW INCIDENCE OF NON-A, NON-B POSTTRANSFUSION HEPATITIS IN LONDON CONFIRMED BY HEPATITIS-C VIRUS SEROLOGY [J].
CONTRERAS, M ;
BARBARA, JAJ ;
ANDERSON, CC ;
RANASINGHE, E ;
MOORE, C ;
BRENNAN, MT ;
HOWELL, DR ;
ALOYSIUS, S ;
YARDUMIAN, A .
LANCET, 1991, 337 (8744) :753-757
[8]   RISK-FACTORS ASSOCIATED WITH HEPATITIS-B OR HEPATITIS-C MARKERS OR ELEVATED ALANINE AMINOTRANSFERASE LEVEL AMONG BLOOD-DONORS ON A TROPICAL ISLAND - THE GUADELOUPE EXPERIENCE [J].
FEST, T ;
VIEL, JF ;
AGIS, F ;
COFFE, C ;
DUPOND, JL ;
HERVE, P .
TRANSFUSION, 1992, 32 (08) :760-763
[9]   HIGH HCV PREVALENCE IN EGYPTIAN BLOOD-DONORS [J].
KAMEL, MA ;
GHAFFAR, YA ;
WASEF, MA ;
WRIGHT, M ;
CLARK, LC ;
MILLER, FD .
LANCET, 1992, 340 (8816) :427-427
[10]   SERUM ALANINE AMINOTRANSFERASE (ALT) AND GAMMA-GLUTAMYL-TRANSFERASE (GAMMA-GT) ACTIVITIES IN NORTH LONDON BLOOD-DONORS [J].
MIJOVIC, V ;
CONTRERAS, M ;
BARBARA, JAJ .
JOURNAL OF CLINICAL PATHOLOGY, 1987, 40 (11) :1340-1344